CF PharmTech, Inc. filed a Next Day Disclosure Return on 28 April 2026, confirming a minor share buyback executed the same day on the Hong Kong Stock Exchange.

• Transaction details: 4,000 ordinary H-shares were repurchased on-market at prices ranging from HK$20.70 to HK$21.04, resulting in a volume-weighted average of HK$20.82 per share. The total consideration paid was HK$0.08 million.

• Impact on share capital: Issued shares (excluding treasury shares) declined marginally to 301.58 million, a 0.0013% reduction from the previous day. Outstanding treasury shares rose to 641,000, while the overall issued share count remained unchanged at 302.22 million.

• Mandate utilisation: Since the current repurchase mandate was approved on 16 December 2025, the company has bought back 641,000 shares, representing 0.2121% of the issued share base on the mandate date. The authorised limit allows for up to 30.22 million shares to be repurchased.

• Regulatory compliance: The company confirmed that all repurchases complied with Hong Kong listing rules and that a 30-day moratorium on new share issues or treasury share disposals is in effect until 28 May 2026.